In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

• 
  
  • Dirk Lange, CEO at Pyramid Labs
  
  
  • Brett Alderson, President & Site Leader at NovaCina
  
  
  • John Cameron, Director, Global Injectables Platform at Corden Pharma
  
  
  • Janet Hoogstraate, CEO at NorthX Biologics
  
  
  
  

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dirk, Brett, John & Janet, focusing on:

• Maximizing GLP-1 manufacturing capacity: Discussing Novo Nordisk’s recent acquisition of Catalent’s manufacturing facilities to bolster GLP-1 production capabilities


• Industry consolidation: What this acquisition means for the pharmaceutical outsourcing industry and its impact on competition among CDMOs


• Meeting surging demand: Exploring how this move positions Novo Nordisk to respond to the rapidly increasing demand for GLP-1 receptor agonists, like those used in diabetes and obesity treatments


• Strategic manufacturing: The implications of integrating Catalent’s capabilities into Novo Nordisk’s operations and what it means for the broader CDMO sector

With GLP-1 drugs at the forefront of diabetes and obesity treatment, Novo Nordisk's strategic acquisition of Catalent aims to strengthen its supply chain and boost production capacity to meet global demand. Our guests provide in-depth insights into how this acquisition could shape the future of drug development and outsourcing across the industry.

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.